Novavax Inc.
Rating
Updated: Aug 10, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The compa...
Latest News
3 days ago · zacks.com
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to KnowIn the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.
4 days ago · zacks.com
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
7 days ago · zacks.com
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowNovavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
11 days ago · zacks.com
Novavax (NVAX) Laps the Stock Market: Here's WhyIn the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
12 days ago · marketbeat.com
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform PivotNovavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
12 days ago · seekingalpha.com
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptNovavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
13 days ago · marketbeat.com
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor ConferenceNovavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healthcare Conference.
13 days ago · seekingalpha.com
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptNovavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
20 days ago · benzinga.com
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M RumorNovavax Inc. (NASDAQ:NVAX) shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.
21 days ago · 247wallst.com
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NVAX